Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 4

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 8
Chunk 4
---
 as a result of the Merger—— —— —— —— 8,320,485— 116,145 — — 116,145 Issuance of common stock from private placements, net—— —— —— —— 5,138,512— 79,513 — — 79,513 Reclassification of warrant liability to equity—— —— —— —— —— 1,918 — — 1,918 Merger transaction costs—— —— —— —— —— (5,070)— — (5,070)Unrealized gain on marketable securities—— —— —— —— —— — — 190 190 Exercise of stock options and common warrants—— —— —— —— 801,9831 4,037 — — 4,038 Vesting of early exercised stock options—— —— —— —— 27,427— 76 — — 76 Share-based compensation—— —— —— —— —— 6,365 — — 6,365 Net loss—— —— —— —— —— — (49,769)— (49,769)Balance as of December 31, 2024—$— —$— —$— —$— 27,518,439$1 $348,901 $(145,014)$196 $204,084 

See accompanying notes to consolidated financial statements.

(1)Retroactively recast for the reverse recapitalization as described in Note 3.

103

Table of Contents

LENZ THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED AND COMMON STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (1)

(in thousands, except share data)

Convertible Preferred and Common StockStockholders' DeficitSeries A Convertible PreferredStockSeries A-1 ConvertiblePreferred StockSeries B Convertible PreferredStockClass B Convertible CommonStockCommon StockAdditionalPaid-inCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncomeStockholders'DeficitSharesAmountSharesAmountSharesAmountSharesAmountSharesAmountBalance as of December 31, 202221,977,282$44,621 2,950,548$9,893 —$— 2,744,184$5,900 1,